Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease
A method of treating Alzheimer's disease (AD) is disclosed. The method comprises electrically stimulating a nerve pathway in a brain region of a subject with at least two high frequency spike bursts of electrical currents, the bursts comprising between 2-20 spikes, wherein a frequency of the spikes in the bursts is between 5-200 msec.
1. A method of treating Alzheimer's disease (AD) in a subject in need thereof, the method comprising:
(a) electrically stimulating a nerve pathway in a brain region of the subject with at least two high frequency spike bursts of electrical currents, wherein a pattern of said high frequency spike bursts is a natural burst pattern of a healthy subject; and
(b) administering to the subject an agent selected from the group consisting of a GABA B receptor agonist, an A 1 receptor agonist, a metabotropic glutamate receptors group II agonist, an M 2 muscarinic agonist, a CB 1 endocannabinoid receptor agonist, Mu opioid receptor agonist, a voltage-dependent antagonist of voltage-gated calcium channels.
2. The method of claim 1 , wherein said electrically stimulating is effected at the entorhinal cortex.
3. The method of claim 1 , wherein said brain region comprises a hippocampus.
4. The method of claim 1 , wherein said natural burst pattern of a healthy subject is a hippocampal natural burst pattern.
5. The method of claim 4 , wherein said hippocampal natural burst pattern is set forth in Table 1.
6. The method of claim 1 , wherein said electrically stimulating does not affect the permeability of the blood brain barrier (BBB).
7. The method of claim 1 , wherein said administering is effected prior to said stimulating.
8. The method of claim 1 , wherein said administering is effected following said stimulating.
9. The method of claim 1 , wherein said administering is effected concomitant with said stimulating.
10. The method of claim 1 , wherein a dose of said agent is selected such that it lowers synaptic transmission of low frequency pulses in the brain to a greater extent than high frequency bursts.
11. The method of claim 1 , wherein said GABA B receptor agonist is selected from the group consisting of baclofen, CGP44532 and CGP35024.
12. The method of claim 1 , wherein said A 1 receptor agonist is selected from the group consisting of 2-Chloro-N-cyclopentyladenosine (CCPA), N-Cyclopentyladenosine (CPA), N-Bicyclo[2.2.1]hept-2-yl-5′-chloro-5′-deoxyadenosine (ENBA), N-[1S,2S)-2-Hydroxycyclopentyl]adenosine, and 2-Chloro-N-cyclopentyl-2′-methyladenosine.
13. The method of claim 1 , wherein said metabotropic glutamate receptor group II agonist is selected from the group consisting of (1R,4R,5S,6R)-4-Amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY 379268),(1S,2S,5R,6S)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY35474), (2R,4R)-4-Aminopyrrolidine-2,4-dicarboxylate and (2S,1′S,2′S)-2-(Carboxycyclopropyl)glycine (L-CCG-I).
14. The method of claim 1 , wherein said CB 1 endocannabinoid receptor agonist is selected from the group consisting of N-(2-Chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide (ACEA), N-(Cyclopropyl)-5Z,8Z,11Z,14Z-eicosatetraenamide (ACPA), rel-5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl] phenol (CP47497) and N-(2-Hydroxyethyl)-7Z,10Z,13Z,16Z-docosatetraenamide.
15. The method of claim 1 , wherein a dose of said agent is selected such that it lowers synaptic transmission of low frequency pulses in the brain to a greater extent than high frequency bursts.
16. A method of treating AD in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an agent selected from the group consisting of a GABA B receptor agonist, an A 1 receptor agonist, a metabotropic glutamate receptors group II agonist, an M 2 muscarinic agonist, a CB 1 endocannabinoid receptor agonist, Mu opioid receptor agonist, a voltage-dependent antagonist of voltage-gated calcium channels and a calcium chelator wherein a dose of said agent is selected such that it lowers synaptic transmission of low frequency pulses in the brain to a greater extent than high frequency bursts.
17. A method of selecting a stimulator useful for the treatment of AD, the method comprising:
(a) contacting brain cells with the stimulator; and
(b) determining an amount of Aβ40 in said brain cells, wherein an increase in an amount of Aβ40 following said contacting is indicative of a stimulator useful for the treatment of AD.
18. The method of claim 17 , wherein said stimulator comprises an electrical stimulator.
19. The method of claim 17 , wherein said stimulator comprises a pharmacological stimulator.
20. The method of claim 17 , further comprising determining an amount of Aβ42 in said brain cells following step (a), wherein an increase in Aβ40: Aβ42 is indicative of stimulant useful for the treatment of AD.
21. The method of claim 19 , wherein said contacting is effected for about 3 hours.
22. A method of treating Alzheimer's disease (AD) in a subject in need thereof, the method comprising:
(a) electrically stimulating a nerve pathway in a brain region of the subject with at least two high frequency spike bursts of electrical currents, said bursts comprising between 2-20 spikes, wherein a frequency of said spikes in said bursts is between 5-200 msec; and
(b) administering to the subject an agent selected from the group consisting of a GABA B receptor agonist, an A 1 receptor agonist, a metabotropic glutamate receptors group II agonist, an M 2 muscarinic agonist, a CB 1 endocannabinoid receptor agonist and a Mu opioid receptor agonist.
23. The method of claim 22 , wherein said GABA B receptor agonist is selected from the group consisting of baclofen, CGP44532 and CGP35024.
24. The method of claim 22 , wherein said A 1 receptor agonist is selected from the group consisting of 2-Chloro-N-cyclopentyladenosine (CCPA), N-Cyclopentyladenosine (CPA), N-Bicyclo[2.2.1]hept-2-yl-5′-chloro-5′-deoxyadenosine (ENBA), N-[(1S,2S)-2-Hydroxycyclopentyl]adenosine, and 2-Chloro-N-cyclopentyl-2′-methyladenosine.
25. The method of claim 22 , wherein said metabotropic glutamate receptor group II agonist is selected from the group consisting of (1R,4R,5S,6R)-4-Amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY379268),(1S,2S,5R,6S)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY35474), (2R,4R)-4-Aminopyrrolidine-2,4-dicarboxylate and (2S,1′S,2′S)-2-(Carboxycyclopropyl)glycine (L-CCG-I).
26. The method of claim 22 , wherein said CB 1 endocannabinoid receptor agonist is selected from the group consisting of N-(2-Chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide (ACEA), N-(Cyclopropyl)-5Z,8Z,11Z,14Z-eicosatetraenamide (ACPA), rel-5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl] phenol (CP47497) and N-(2-Hydroxyethyl)-7Z,10Z,13Z,16Z-docosatetraenamide.
27. The method of claim 22 , wherein a dose of said agent is selected such that it lowers synaptic transmission of low frequency pulses in the brain to a greater extent than high frequency bursts.